Background: Several studies have shown that high-density lipoprotein (HDL) cholesterol provides protection against bacterial infections. Our aim was to investigate the influence of HDL cholesterol levels on the risk of developing in-hospital infectious complications after an acute ischemic stroke (IS) as well as the possible effect of prestroke statin treatment on this association. Methods and Results: Observational study that included consecutive IS patients during a 5-year period (2006-2010). We analyzed vascular risk factors, prestroke treatments (including statins), laboratory data (including HDL cholesterol levels), stroke severity, and the development of infectious complications (pneumonia, urinary tract infection and sepsis). A multivariate analysis that included HDL cholesterol levels, prior statin treatment and the interaction between both variables was performed to identify those factors associated with the presence of infectious complications. A total of 1,385 patients were included, 130 of whom (9.4%) developed in-hospital infections. The receiver operating characteristic curve showed the predictive value of HDL cholesterol with an area under the curve of 0.597 (95% CI, 0.526-0.668; p = 0.006) and pointed to 38.5 mg/dl of HDL cholesterol (65.5% sensitivity and 53.4% specificity) as the optimal cutoff level for developing infectious complications during hospitalization. An HDL cholesterol level ≥38.5 mg/dl was an independent predictive factor for lower risk of infection (OR 0.308; 95% CI 0.119-0.795), whereas prestroke statin treatment was not associated with the development of infection. Conclusions: An HDL cholesterol level ≥38.5 mg/dl was independently associated with lower risk for developing infectious complications in acute IS patients. Statins do not influence this association.

Keywords:
High-density lipoprotein cholesterol, Stroke, In-hospital complications, Infection
1.
Ionita CC, Siddiqui AH, Levy EI, Hopkins LN, Snyder KV, Gibbons KJ: Acute ischemic stroke and infections. J Stroke Cerebrovasc Dis 2011;20:1-9.
2.
Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D: Post-stroke infection: a systematic review and meta-analysis. BMC Neurol 2011;11:110.
3.
Meisel A, Meisel C, Harms H, Hartman O, Ulm L: Predicting post-stroke infections and outcome with blood-based immune and stress markers. Cerebrovasc Dis 2012;33:580-588.
4.
Kumar S, Selim MH, Caplan LR: Medical complications after stroke. Lancet Neurol 2010;9:105-118.
5.
Hug A, Dalpke A, Wieczorek N, Giese T, Lorenz A, Auffarth G, Liesz A, Veltkamp R: Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 2009;40;3226-3232.
6.
Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM: High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001;103:2283-2288.
7.
Gazi IF, Apostolou FA, Liberopoulos EN, Filippatos TD, Tellis CC, Elisaf MS, Tselepis AD: Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein. Lipids 2011;46:953-960.
8.
Apostolou F, Gazi IF, Kostoula A, Tellis CC, Tselepis AD, Elisaf M, Liberopoulos EN: Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res 2009;50:2532-2539.
9.
Lüthold S, Berneis K, Bady P, Müller B: Effects of infectious disease on plasma lipids and their diagnostic significance in critical illness. Eur J Clin Invest 2007;37:573-579.
10.
Gordon SM, Hofmann S, Askew DA, Davidson WS: High-density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol Metab 2011;22:9-15.
11.
Villarroel F, Bastías A, Casado A, Amthauer R, Concha MI: Apolipoprotein A-I, an antimicrobial protein in Oncorhynchus mykiss: evaluation of its expression in primary defence barriers and plasma levels in sick and healthy fish. Fish Shellfish Immunol 2007;23:197-209.
12.
Caipanq CM, Hynes N, Puanqkaew J, Brinchmann MF, Kiron V: Intraperitoneal vaccination of Atlantic cod, Gadus morhua with heat-killed Listonella anguillarum enhances serum antibacterial activity and expression of immune response genes. Fish Shellfish Immunol 2008;24:314-322.
13.
Grunfeld C, Feingold KR: HDL and innate immunity: a tale of two apolipoproteins. J Lipid Res 2008;49:1605-1606.
14.
Yu BL, Wang SG, Peng DQ, Zhao SP: HDL and immunomodulation: an emerging role of HDL against atherosclerosis. Immunol Cell Biol 2012;88:285-290.
15.
Haas MJ, Mooradian AD: Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease. Diabetes Metab Res Rev 2010;26:90-99.
16.
Delgado-Rodríguez M, Medina-Cuadros M, Martínez-Gallego G, Sillero-Arenas M: Total cholesterol, HDL cholesterol and risk of nosocomial infection: a prospective study in surgical patients. Infect Control Hosp Epidemiol 1997;18:9-18.
17.
Canturk NZ, Canturk Z, Okay E, Yirmibesoglu O, Eraldemir B: Risk of nosocomial infections and effects of total cholesterol, HDL cholesterol in surgical patients. Clin Nutr 2002;21:431-436.
18.
Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Danon A: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-885.
19.
Chua D, Tsang RS, Kuo IF: The role of statin therapy in sepsis. Ann Pharmacother 2007;41:647-652.
20.
Montaner J, Chacón P, Krupinski J, Rubio F, Millán M, Molina CA, Hereu P, Quintana M, Alvarez-Sabin J: Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008;15:82-90.
21.
Bogousslavsky J, van Melle G, Regli F: The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke 1988;19:1083-1092.
22.
Arboix A, Alvarez-Sabin J, Soler L: Stroke. Classification and diagnostic criteria. Ad hoc Editorial Committee of the Task Force on Cerebrovascular Diseases of SEN. Neurologia 1998;13:3-10.
23.
Hackam DG, Mamdani M, Li P, Redelmeier DA: Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006;367:413-418.
24.
Rodríguez de Antonio LA, Martínez-Sánchez P, Martínez-Martínez MM, Cazorla-García R, Sanz-Gallego I, Fuentes B, Díez-Tejedor E: Previous statins treatment and risk of post-stroke infections. Neurologia 2011;26:150-156.
25.
Yeh PS, Lin HJ, Chen PS, Lin SH, Wang WM, Yang CM, Li YH: Effect of statin treatment on three-month outcomes in patients with stroke-associated infection: a prospective cohort study. Eur J Neurol 2012;19:689-695.
26.
Blank N, Schiller M, Krienke S, Busse F, Schätz B, Ho AD, Kalden JR, Lorenz HM: Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J Immunol 2007;179:3613-3621.
27.
Fuentes B, Díez-Tejedor E, Ortega-Casarrubios MA, Martínez P, Lara M, Frank A: Consistency of the benefits of stroke units over years of operation: an 8-year effectiveness analysis. Cerebrovasc Dis 2006;21:173-179.
28.
Alvarez-Sabín J, Ribó M, Masjuan J, Tejada JR, Quintana M, Investigadores del Estudio PRACTIC: Hospital care of stroke patients: importance of expert neurological care. Neurologia 2011;26:510-517.
29.
González MJ, Falip R, Martín R, Matías-Guiu J: A comparative study of mortality and infectious complications in patients admitted to neurological and general wards. Rev Neurol 1995;23:385-389.
30.
Govan L, Langhorne P, Weir CJ: Does the prevention of complications explain the survival benefit of organized inpatient (stroke unit) care? Further analysis of a systematic review. Stroke 2007;38:2536-2540.
31.
Indredavik B, Fjaertoft H, Ekeberg G, Løge AD, Mørch B: Benefit of an extended stroke unit service with early supported discharge: a randomized, controlled trial. Stroke 2000;31:2989-2994.
32.
Fjaertoft H, Indredavik B, Lydersen S: Stroke unit care combined with early supported discharge: long-term follow-up of a randomized controlled trial. Stroke 2003;34:2687-2691.
33.
Roth JE, Lovell L, Harvey RL, Heiemann AW, Semik P, Diaz S: Incidence of and risk factors for medical complications during stroke rehabilitation. Stroke 2001;32:523-529.
34.
Indredavik B, Rohweder G, Naalsund E, Lydersen S: Medical complications in a comprehensive stroke unit and an early supported discharge service. Stroke 2008;39:414-420.
35.
Langhorne P, Stott DJ, Roberson L, MacDonald J, Jones L, McAlpine C, Dick F, Taylor GS, Murray G: Medical complications after stroke: a multicenter study. Stroke 2000;31:1223-1229.
36.
Kalra L, Yu G, Wilson K, Roots P: Medical complications during stroke rehabilitation. Stroke 1995;26:990-994.
37.
Davenport RJ, Dennis MS, Welwood I, Warlow C: Complications after acute stroke. Stroke 1996;27:415-420.
38.
Minnerup J, Schäbitz WR: Improving outcome after stroke: time to treat new targets. Stroke 2012;43:295-296.
39.
Martínez-Sánchez P, Fuentes B, Medina-Báez J, Grande M, Llorente C, Parrilla P, Fuster A, Gil A, Sánchez M, Olguín C, García-Caballero J, Díez-Tejedor E: Development of an acute stroke care pathway in a hospital with stroke unit. Neurologia 2010;25:17-26.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.